Cartherics is a biotechnology company focused on developing innovative cancer therapies. We have developed CAR-T cells that are derived from the blood of cancer patients that are genetically modified and expanded for their therapy for solid tumours (ovarian and gastric cancers).  Our primary focus is now on therapies that involve gene editing stem cells made from donor umbilical cord blood and the manufacturing of immune killer cells that can be available to cancer patients “off-the-shelf”.